



Theratechnologies and TaiMed Biologics sign exclusive Marketing and Distribution Agreement for Ibalizumab

March 18, 2016

Theratechnologies inc. (TSX: TH) and TaiMed Biologics, Inc. today announced a 12-year collaboration agreement to market and distribute ibalizumab in the United States and in Canada. Ibalizumab is a novel CD4-directed HIV entry-inhibitor and is the first humanized monoclonal antibody in clinical trials for the treatment of HIV.